efimosfermin - Search News

News

GSK, Boston and efimosfermin

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in success-based milestone payments. The drugmaker will also be responsible for success-based milestone payments as well as tiered royalties for efimosfermin owed to Novartis Pharma.

PMLive · 2h

Zacks Investment Research on MSN · 1h

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug

Medical Dialogues · 2h

GSK to acquire liver disease drug Efimosfermin for up to USD 2 billion

1don MSN

GSK to buy efimosfermin for up to $2 billion

British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...

Pharmabiz9h

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...

Medscape6d

Once-Monthly Efimosfermin Leads to Significant MASH Improvement in Phase 2 Trial

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

GSK, Boston and efimosfermin

Trending now